EMERYVILLE, Calif., May 25 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. , today announced that Paul E. Freiman, President and Chief Executive Officer, will deliver a corporate presentation at the FBR 2006 Growth Investor Conference on May 31, 2006, in New York City.
Mr. Freiman’s presentation will take place on Wednesday, May 31, at 12:45 p.m. and will be available at the following link:
http://www.shareholder.com/ntii/medialist.cfm
The web cast will be available on NTI’s website (www.ntii.com) for 60 days after the event.
About Neurobiological Technologies, Inc.
NTI is a drug development company focused on the clinical evaluation and regulatory approval of neuroscience drugs. The company’s strategy is to in- license and develop early- and later-stage drug candidates that target major medical needs and which can be rapidly commercialized. NTI’s experienced management team oversees the human clinical trials necessary to establish preliminary evidence of efficacy. We anticipate that we will continue to acquire and develop late-stage neurologic drug candidates and will develop the resources to market these drugs in selected world regions. Our goal is to develop and market drug candidates in the United States, Europe and Asia and we may seek partnerships with pharmaceutical and biotechnology companies to assist us.
Neurobiological Technologies, Inc.
CONTACT: Paul E. Freiman, President & CEO of Neurobiological Technologies,Inc., +1-510-595-6000; or Cheryl Schneider, VP - Investor Relations, ofPorter, Le Vay & Rose, Inc., +1-212-564-4700, for NeurobiologicalTechnologies, Inc.
Web site: http://www.ntii.com//
